Gender analysis of the pivotal results of the Medtronic Talent Thoracic Stent Graft System (VALOR) trial

TEVAR with the Talent device provided similar rates of 365-day mortality and morbidity for men and women. Although female patients had higher rates of periprocedural complications, they also more often had successful aneurysm treatment at the 1-year follow-up.